{"filing":{"accession_number":"0001193125-26-261910","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"d85703d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526261910/d85703d8k.htm"},"events":[{"id":6219,"run_id":5457,"accession_number":"0001193125-26-261910","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Jaguar Health held its 2026 Annual Meeting of Stockholders on June 8, 2026, with shareholders voting on five proposals including election of a Class II director, ratification of auditors, and approval of dilutive issuances to C/M Capital Master Fund representing more than 19.99% of outstanding shares under two separate agreements (ELOC and Preferred Stock Purchase Agreement).","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5290,"accession_number":"0001193125-26-261910","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the final results of Jaguar Health's 2026 Annual Meeting of Stockholders, including voting outcomes on five proposals: election of a Class II director, ratification of auditors, and critically, approval of dilutive issuances to C/M Capital Master Fund representing more than 19.99% of outstanding shares under two separate agreements (ELOC and Preferred Stock Purchase). The disclosure of shareholder vote results on material matters—particularly the approval of substantial equity issuances—is a core shareholder_vote_results event that would materially affect investor assessment of ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:43:11.264596+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5291,"accession_number":"0001193125-26-261910","item_number":"7.01","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses results of an Annual Meeting via press release issued on June 8, 2026. This is a classic shareholder_vote_results disclosure under Item 5.07, even though it is being furnished under Item 7.01 (Regulation FD Disclosure). The substance of the disclosure—announcement of Annual Meeting results—is material to investors as it typically covers director elections, compensation votes, and other shareholder-approved matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:43:11.264596+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5290,"accession_number":"0001193125-26-261910","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the final results of Jaguar Health's 2026 Annual Meeting of Stockholders, including voting outcomes on five proposals: election of a Class II director, ratification of auditors, and critically, approval of dilutive issuances to C/M Capital Master Fund representing more than 19.99% of outstanding shares under two separate agreements (ELOC and Preferred Stock Purchase). The disclosure of shareholder vote results on material matters—particularly the approval of substantial equity issuances—is a core shareholder_vote_results event that would materially affect investor assessment of ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:43:11.264596+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-08"},{"id":5291,"accession_number":"0001193125-26-261910","item_number":"7.01","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses results of an Annual Meeting via press release issued on June 8, 2026. This is a classic shareholder_vote_results disclosure under Item 5.07, even though it is being furnished under Item 7.01 (Regulation FD Disclosure). The substance of the disclosure—announcement of Annual Meeting results—is material to investors as it typically covers director elections, compensation votes, and other shareholder-approved matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:43:11.264596+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-06-08"}]}